What it's for (Indications)
- Sacubitril + valsartan is specifically indicated for the treatment of chronic heart failure in adults.
- Its primary established use is for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), classified as New York Heart Association (NYHA) Class II-IV, to significantly reduce the risk of cardiovascular death and hospitalization for heart failure.
- This therapeutic agent has demonstrated superior efficacy compared to angiotensin-converting enzyme (ACE) inhibitors in this population, becoming a cornerstone of guideline-directed medical therapy.
- More recently, evidence supports its use for specific patients with chronic heart failure with preserved ejection fraction (HFpEF) to reduce the risk of cardiovascular death and hospitalization for heart failure, broadening its clinical utility in the complex management of heart failure syndromes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for sacubitril + valsartan is typically 49 mg sacubitril / 51 mg valsartan orally twice daily. For patients who are not currently taking an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), or those with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or moderate hepatic impairment, a lower initial dose of 24 mg sacubitril / 26 mg valsartan orally twice daily is advised to minimize the risk of adverse effects such as hypotension. The dose should be gradually titrated upwards, approximately every 2 to 4 weeks, to the target maintenance dose of 97 mg sacubitril / 103 mg valsartan twice daily, as tolerated by the patient. It is crucial to monitor blood pressure, renal function, and serum potassium levels closely during dose initiation and titration to ensure patient safety and optimize therapeutic benefit. A 36-hour washout period is mandatory after discontinuing an ACE inhibitor before initiating sacubitril + valsartan to mitigate the risk of angioedema. |
Safety & Warnings
Common Side Effects
- The most frequently reported adverse reactions associated with sacubitril + valsartan include symptomatic hypotension, which can manifest as dizziness or lightheadedness, and may necessitate dose adjustment or discontinuation.
- Hyperkalemia, an elevated level of potassium in the blood, is also common, especially in patients with renal impairment or those concomitantly receiving potassium-sparing diuretics or potassium supplements.
- Renal impairment, characterized by an increase in serum creatinine, can occur or worsen, requiring vigilant monitoring of kidney function.
- Other common side effects include cough, dizziness, and fatigue.
- Less common but serious adverse events include angioedema, a severe swelling of the face, lips, tongue, and throat that can be life-threatening, and syncope (fainting).
- Patients should be educated on recognizing the signs of angioedema and advised to seek immediate medical attention if they occur.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** When pregnancy is detected, sacubitril + valsartan should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system, including angiotensin receptor blockers like valsartan (a component of sacubitril + valsartan), can cause injury and death to the developing fetus. There have been several reports in the medical literature of fetal death, oligohydramnios (reduced amniotic fluid), fetal lung hypoplasia, skeletal deformations, and other serious birth defects when such drugs are used during the second and third trimesters of pregnancy. Even exposure limited to the first trimester carries a potential risk. Therefore, women of childbearing potential should be made aware of the potential risks to the fetus and appropriate contraception should be used while taking this medication. If pregnancy is confirmed, the medication should be stopped immediately, and the patient should be counseled regarding the potential risk to the fetus and referred for appropriate monitoring.
- Several significant warnings are associated with sacubitril + valsartan.
- The potential for symptomatic hypotension is considerable, particularly upon initiation or during dose escalation, necessitating careful blood pressure monitoring and potential dose adjustments.
- Patients should be advised about symptoms of hypotension and how to manage them.
- Worsening renal function, including acute renal failure, has been observed, particularly in patients with pre-existing renal impairment or those concurrently receiving other nephrotoxic agents; regular monitoring of kidney function and serum potassium is essential.
- Hyperkalemia is another concern, especially in patients with impaired renal function, diabetes, or those on potassium-elevating medications.
- The risk of angioedema, a serious and potentially fatal hypersensitivity reaction, is increased, particularly in patients with a history of angioedema related to ACE inhibitor or ARB therapy, making such a history a contraindication.
- There is also a significant risk of embryo-fetal toxicity, which is detailed in the Black Box Warning.
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with an ARB, ACE inhibitor, or aliskiren is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal function changes.
How it Works (Mechanism of Action)
Sacubitril + valsartan is a sophisticated combination medication that acts as an angiotensin receptor-neprilysin inhibitor (ARNI), employing a dual, complementary mechanism to manage heart failure. Valsartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor. This blockade prevents the detrimental effects of angiotensin II, including vasoconstriction, aldosterone release, myocardial remodeling, and sodium/water retention, thereby counteracting the maladaptive activation of the renin-angiotensin-aldosterone system (RAAS). Concurrently, sacubitril is a neprilysin inhibitor. Neprilysin is an enzyme responsible for degrading various endogenous vasoactive peptides, including natriuretic peptides (e.g., atrial natriuretic peptide, brain natriuretic peptide), bradykinin, and adrenomedullin. By inhibiting neprilysin, sacubitril increases the levels of these beneficial peptides, leading to vasodilation, natriuresis (excretion of sodium in the urine), diuresis (increased urine production), and inhibition of pathological cardiac remodeling. The synergistic action of both components provides enhanced cardiovascular benefits beyond what either component could achieve alone, improving hemodynamics and reversing the progression of heart failure.